Supply Chain Intelligence

Maze Therapeutics, Inc. Supply Chain

MAZE supply chain intelligence for Maze Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

MAZE ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

1Suppliers
5Customers
3Debt Items
20Related Chains

Maze Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
DYN Dyne Therapeutics, Inc. 72% Reciprocal relationship from DYN graph: Reciprocal relationship from MAZE graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disru…

Maze Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
NEUROCRINE-BIOSCIENCES-INC NEUROCRINE-BIOSCIENCES-INC 92% the Company granted Neurocrine an exclusive worldwide license to a discovery research program targeting ATXN2, or the Neurocrine License Agreement
SHIONOGI SHIONOGI 92% the Company granted Shionogi an exclusive, worldwide, sublicensable license to research, develop, manufacture and commercialize MZE001 and certain other small molecule compounds modulating glycogen s…
NBIX Neurocrine Biosciences, Inc. 85% . Potential sales milestones and royalties on net product sales will be recognized in the same period that the underlying net product sales occur as they were determined to relate to the license. The…
NBIX Neurocrine Biosciences, Inc. 85% Reciprocal relationship from NBIX graph: Reciprocal relationship from MAZE graph: . Potential sales milestones and royalties on net product sales will be recognized in the same period that the underl…
DYN Dyne Therapeutics, Inc. 72% Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number…

Maze Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
MAZE-DEBT-10871 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.
MAZE-DEBT-16953 Warrants outstanding: 1000 90% xbrl warrant detail from xbrl 2025-12-31.
MAZE-DEBT Debt stack $61.2M 90% Market cache reports total debt of $61.2M.

Maze Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Maze Therapeutics, Inc..

Maze Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
MAZE-OWNER-JANUS-HENDERSON-GROUP-PLC JANUS HENDERSON GROUP PLC 90% 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 169 tracked holders.

Maze Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
DYN Dyne Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
HTGC Hercules Capital, Inc. 100.00 1 ['receiving']
BLRX BioLineRx Ltd. 100.00 2
BCYC Bicycle Therapeutics plc 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
DBVTF DBV TECHNOLOGIES 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
CPRX Catalyst Pharmaceuticals, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
ATOS Atossa Therapeutics, Inc. 100.00 2
View MAZE supply chain intel →

Explore the full interactive supply chain map for Maze Therapeutics, Inc..

Open MAZE supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map